Prostaglandin E<sub>2</sub>–Induced Immune Exhaustion and Enhancement of Antiviral Effects by Anti–PD-L1 Antibody Combined with COX-2 Inhibitor in Bovine Leukemia Virus Infection

Yamato Sajiki,* Satoru Konnai,*† Tomohiro Okagawa,‡ Asami Nishimori,* Naoya Maekawa, † Shinya Goto,* Kei Watari, Erina Minato,‡ Atsushi Kobayashi,‡ Junko Kohara,§ Shinji Yamada,¶ Mika K. Kaneko,§ Yukinari Kato,§ Hirofumi Takahashi,|| Nobuhiro Terasaki,|| Akira Takeda,|| Keiichi Yamamoto,†# Mikihiro Toda,†,** Yasuhiko Suzuki,†,†+,‡‡ and Kazuhiko Ohashi*†

Bovine leukemia virus (BLV) infection is a chronic viral infection of cattle and endemic in many countries, including Japan. Our previous study demonstrated that PGE<sub>2</sub>, a product of cyclooxygenase (COX) 2, suppresses Th1 responses in cattle and contributes to the progression of Johne disease, a chronic bacterial infection in cattle. However, little information is available on the association of PGE<sub>2</sub> with chronic viral infection. Thus, we analyzed the changes in plasma PGE<sub>2</sub> concentration during BLV infection and its effects on proviral load, viral gene transcription, Th1 responses, and disease progression. Both COX2 expression by PBMCs and plasma PGE<sub>2</sub> concentration were higher in the infected cattle compared with uninfected cattle, and plasma PGE<sub>2</sub> concentration was positively correlated with the proviral load. BLV Ag exposure also directly enhanced PGE<sub>2</sub> production by PBMCs. Transcription of BLV genes was activated via PGE<sub>2</sub> receptors EP2 and EP4, further suggesting that PGE<sub>2</sub> contributes to disease progression. In contrast, inhibition of PGE<sub>2</sub> production using a COX-2 inhibitor activated BLV-specific Th1 responses in vitro, as evidenced by enhanced T cell proliferation and Th1 cytokine production, and reduced BLV proviral load in vivo. Combined treatment with the COX-2 inhibitor meloxicam and anti-programmed death-ligand 1 Ab significantly reduced the BLV proviral load, suggesting a potential as a novel control method against BLV infection. Further studies using a larger number of animals are required to support the efficacy of this treatment for clinical application. The Journal of Immunology, 2019, 203: 1313–1324.

Prostaglandin E<sub>2</sub> is an inflammatory mediator produced by cyclooxygenase (COX) enzymes (COX-1 and COX-2) from arachidonic acid (1). COX-1 is a constitutive enzyme expressed in many tissues and involves in a multitude of physiological processes (2), whereas COX-2 is an inducible enzyme regulated by inflammatory cytokines via the activation of NF-κB (3). The level of PGE<sub>2</sub> is regulated not only by its synthesis but also by its degradation. 15-HydroxyPG dehydrogenase (15-PGDH), encoded by the HPGD gene, is a key enzyme for PGE<sub>2</sub> inactivation (4, 5). PGE<sub>2</sub> suppresses the activity of immune cells, such as T cells (especially Th1 cells), NK cells, and dendritic cells, via EP2 and EP4 receptors, thereby contributing to immune evasion during chronic infection (6, 7). By contrast, by reducing PGE<sub>2</sub> synthesis, COX-2 inhibitors activate immune responses in vitro and in vivo (8, 9). Thus, COX-2 inhibition is considered a potential immunotherapy for chronic infections.

Bovine leukemia virus (BLV), which is a member of the genus of Deltaaretrovirus, causes enzootic bovine leukosis (EBL) and is closely related to human T cell leukemia virus type 1 (10). This virus generally infects B cells of cattle, and most BLV-infected animals are required to support the efficacy of this treatment for clinical application.

*Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan; †Department of Advanced Pharmaceutics, Faculty of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan; ‡Department of Veterinary Clinical Medicine, Faculty of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan; Animal Research Center, Agriculture Research Department, Hokkaido Research Organization, Shinotoku 018-0038, Japan; †Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan; †Shibecha Branch, Kushiro Central Office, Hokkaido Higashi Agricultural Mutual Aid Association, Shibecha 083-2311, Japan; †Research and Development Center, Fuso Pharmaceutical Industries, Ltd., Osaka 536-8523, Japan; ††New Business and International Business Development, Fuso Pharmaceutical Industries, Ltd., Osaka 536-8523, Japan; ‡Division of Bioresources, Research Center for Zoonosis Control, Hokkaido University, Sapporo 060-019, Japan; †‡Global Station for Zoonosis Control, Global Station for Collaborative Research and Education, Hokkaido University, Sapporo 001-0019, Japan

ORCID: 0000-0002-1391-9732 (T.O.); 0000-0003-3936-7515 (A.N.); 0000-0002-0666-8655 (E.M.); 0000-0001-5385-8201 (Y.K.); 0000-0002-1313-1494 (Y. Suzuki).

Received for publication April 1, 2019. Accepted for publication June 26, 2019.

This work was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science, by Research Project for Improving Animal Disease Prevention Technologies to Combat Antimicrobial Resistance 2017–2021 FY, and by grants from the Project of the NARO, Bio-oriented Technology Research Advancement Institution (Research Program on Development of Innovative Technology 26058 BC [to S.K.] and Special Scheme Project on Regional Developing Strategy, Grant 16017557 [to S.K.]). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Address correspondence and reprint requests to Dr. Satoru Konnai, Faculty of Veterinary Medicine, Hokkaido University, Kita-18 Nishi-9, Kita-ku, Sapporo, Hokkaido 060-0818, Japan. E-mail address: konnai@vetmed.hokudai.ac.jp

The online version of this article contains supplemental material.

Abbreviations used in this article: AL, aleukemic; BLV, bovine leukemia virus; chAb, chimeric Ab; COX, cyclooxygenase; CRE, cAMP-response element; EBL, enzootic bovine leukosis; FLK, fetal lamb kidney, LAG-3, lymphocyte activation gene 3; PD-1, programmed death 1; PD-L1, programmed death-ligand 1; PD, persistent lymphocytosis; qPCR, quantitative real-time PCR.

This article is distributed under The American Association of Immunologists, Inc., Reuse Terms and Conditions for Author Choice articles.
cattle are asymptomatic carriers of the virus or aleukemic (AL). However, ∼30% of the infected cattle show persistent lymphocytosis (PL), characterized by nonmalignant polyclonal expansion of infected B cells in peripheral blood. Less than 5% of the infected cattle develop EBL, characterized by fatal lymphoma or lymphosarcoma after extended latency periods of 5–10 years (11). BLV infection is highly prevalent in many countries, including Japan, and several reports have demonstrated that the seroprevalence of BLV in Japanese cattle is increasing because of the lack of an effective treatment or vaccine (12). Thus, the development of a new control method for BLV infection is required to guarantee the continued supply of livestock and livestock production.

The Th1 response is critical for the control of BLV infection. During BLV infection, suppression of both CD4+ T cell proliferation and cytotoxic immune response against BLV Ags is associated with disease progression (13, 14). To develop a novel strategy for effective control of BLV infection, our recent studies have examined the detailed mechanisms of immune dysfunction in BLV infection. Upregulation of immunoinhibitory molecules, such as programmed death 1 (PD-1), programmed death-ligand 1 (PD-L1), lymphocyte activation gene 3 (LAG-3), T cell Ig domain and mucin domain-3 (Tim-3), and CTL Ag-4 (CTLA-4), was shown to suppress BLV-specific Th1 responses and promote disease progression (15–19). Alternatively, Ab-mediated blockade of the PD-1/PD-L1 pathway significantly reduced the viral load in BLV-infected cattle (20, 21), suggesting that therapy targeting immunoinhibitory molecules, such as PD-1 and PD-L1, may be a novel control strategy against BLV infection. However, it is still unknown how these molecules are upregulated during BLV infection.

Our previous report has shown that PGE2 inhibits the Th1 response and induces the expression of PD-L1 in cattle (22). In addition, we showed that PGE2 is associated with the progression of Johne disease, a bovine chronic infection caused by Mycobacterium avium subsp. paratuberculosis, and that a COX-2 inhibitor can activate Th1 responses in cattle with Johne disease. Furthermore, the combined treatment with an anti–PD-L1 Ab and a COX-2 inhibitor strongly enhanced the antiviral effects during BLV infection (23). Therefore, in this study, we analyzed the kinetics of PGE2 in BLV infection, the association of PGE2 with viral progression, and the antiviral effects of a COX-2 inhibitor in vitro and in vivo. Finally, we also tested whether a combined blockade of the PGE2 and PD-1/PD-L1 pathways in vitro and in vivo can enhance antiviral effects during BLV infection.

Materials and Methods

Cell preparation

Blood samples of BLV-infected and uninfected cattle were obtained from several farmers and veterinarians in Hokkaido, Japan. Infection was confirmed by detection of the provirus using nested PCR targeting the viral long terminal repeat (16) and by detection of the anti-BLV Ab using a commercial ELISA (JNC, Tokyo, Japan). The leukocyte numbers in BLV-infected cattle were counted using a CellTac FLK−BLV; 2% heat-inactivated culture supernatant of FLK−BLV. CD14+ and CD21+ cells were freshly isolated from bovine PBMCs using BD IMagnet (LightCycler 480 System II; Roche Diagnostic, Mannheim, Germany) with SYBR Premix DimerEraser (Takara Bio), following the manufacturer’s instructions. Internal control genes were β-actin (ACTB) and GAPDH. All primer sequences for PCR are listed in Table I. To examine whether the expression levels of viral genes g51, G4, and R3 are increased by PGE2 signaling, the PBMCs of BLV-infected cattle were incubated in the presence of PGE2 (1 μM; Cayman Chemical, MI), EP2 agonist (1 μg/ml, Butaprost (free acid), Cayman Chemical) or EP4 agonist (1 μg/ml, Rivenprost; Cayman Chemical) at 37°C under 5% CO2 for 3 d and collected, and the expression levels were quantified by qPCR as described above. To measure the proviral loads of samples from BLV-infected cattle, qPCR was performed as previously described, with slight modifications (27). Briefly, genomic DNA was extracted from the PBMCs of BLV-infected cattle using the Wizard Genomic DNA Purification Kit (Promega, Madison, WI). The DNA concentration was measured by UV absorbance at 260 nm using a NanoDrop 8000 Spectrophotometer (Thermo Fisher Scientific). Amplification was conducted in a reaction mixture containing 5 μl of 2× Cycleave PCR Reaction Mix SP (Takara Bio), 0.5 μl of Probe/Primer Mix for BLV (Takara Bio), 1 μl of template DNA, and 3.5 μl of RNase-free distilled water (Takara Bio) using a LightCycler 480 System II. The PCR condition was 95°C for 10 s, followed by amplification of the template for 55 cycles at 95°C for 5 s and 64°C for 30 s. Serial dilutions of BLV Positive Control (Takara Bio) were used to generate calibration curves to determine the BLV provirus copy number. Each DNA sample was tested in triplicate, and the reported values are the mean number of copies per 50 ng of genomic DNA.

Quantitation of PGE2 by ELISA

The concentration of PGE2 was measured in plasma or serum samples from BLV-infected and uninfected cattle using the PGE2 Express ELISA Kit (Cayman Chemical) as described previously (22). To assess whether the BLV Ag promotes PGE2 production, PBMCs (4 × 106 cells per well) from infected and uninfected cattle were incubated with the BLV Ag (fetal lamb kidney[FLK]−BLV; 2% heat-inactivated culture supernatant of FLK−BLV cells) at 37°C under 5% CO2 for 6 d. Culture supernatants were collected, and the concentration of PGE2 was measured by ELISA. To compare PGE2 production, the total PBMCs, CD14+ cells and CD21+ cells (5 × 105 cells per well) were incubated separately at 37°C under 5% CO2 for 3 d, and the culture supernatant was collected for measurement of PGE2 concentration by ELISA as described above.

Immunohistochemical assay of PD-L1 and PGE2

Immunohistochemical assays were performed as previously described, with modifications (22). Briefly, sections of superficial cervical lymph nodes from healthy BLV-infected cattle (Holstein, female, 75-mo old) and peripheral mass lesions from EBL cattle (Holstein, female, 24-mo old) were subjected to immunohistochemical staining for PGE2 and PD-L1 using an anti-PGE2 polyclonal Ab (ab2318; Abcam, Cambridge, U.K.) and anti-PD-L1 mAb (6C11-3A11, Rat IgG2a; 22). Cattle exhibiting tumors were diagnosed with EBL as described previously (28, 29). Additionally, the tumor mass lesion was confirmed as B cell lymphoma by immunohistochemical staining with an anti-CD20 polyclonal Ab (PAS-16701; Thermo Fisher Scientific; data not shown).

In vitro analysis of immunostimulation by COX-2 inhibition

To evaluate the immunostimulatory effects of COX-2 inhibition, PBMCs (4 × 105 cells per well) from BLV-infected cattle were labeled with 0.2 μM CFSE and incubated with 1 μM meloxicam (Sigma-Aldrich) or DMSO as a
vehicle control (Nacalai Tesque, Kyoto, Japan) at 37°C under 5% CO₂ for 6 d in the presence of FLK–BLV. After incubation, the concentrations of IFN-γ and TNF-α in the medium were measured by ELISA, and cell proliferation was analyzed by FACS based on CFSE staining strength as described previously (22).

In vitro analysis of immunostimulation by combined COX-2 inhibition and PD-L1 blockade

To examine the immunostimulatory effects of combined COX-2 inhibition plus anti–PD-L1 Abs treatment in vitro, PBMCs (4 × 10⁵ cells per well) from BLV-infected cattle were CFSE labeled and incubated with 1 μM meloxicam and 10 μg/ml anti–PD-L1 Ab in the presence of FLK–BLV for 6 d in DMEM. rat IgG (Sigma-Aldrich), or bovine IgG (Sigma-Aldrich) was used as negative control. Heat-inactivated culture supernatant of FLK cells was used as a negative control Ag. Two forms of anti–PD-L1 Ab, namely anti–PD-L1 mAb (4G12) with the C region of rat IgG2a and Igk was used as a negative control. Heat-inactivated culture supernatant of FLK cells was used as a negative control Ag. Two forms of anti–PD-L1 Ab, namely anti–PD-L1 mAb (4G12) with the C region of rat IgG2a and Igk and anti–PD-L1 chimeric Ab (chAb; BochG12) with the C region of bovine IgG1 (mutated to reduce Ab-dependent cellular toxicity), and Igλ (21) were used to evaluate the combination effects. After 6 d, the concentration of IFN-γ was measured by ELISA, and cell proliferation was analyzed by FACS analysis of CFSE labeling as described above.

Evaluation of COX-2 inhibitor administration for reducing viral load in BLV-infected cattle

To examine the antiviral efficacy of COX-2 inhibition in vivo, three BLV-infected cattle (Table II) were administered 0.5 mg/kg meloxicam (Metacam; Boehringer Ingelheim, Ingelheim, Germany) by s.c. injection once weekly for a total of nine doses (animals #1 and #2) or a total of five doses (animal #3). Animals #1–3 were launched for this experiment and kept separately at the three different locations: in a private dairy farm (Shibecha, Hokkaido, Japan), a biosafety level 1 animal facility at the Animal Research Center, Agricultural Research Department, Hokkaido Research Organization (Shintoku, Hokkaido, Japan), and an animal facility at the Faculty of Veterinary Medicine, Hokkaido University (Sapporo, Hokkaido, Japan). These animal experiments were approved by the Ethics Committee of the Animal Research Center, Agricultural Research Department, Hokkaido Research Organization, and the Ethics Committee of the Faculty of Veterinary Medicine, Hokkaido University. Peripheral blood samples were collected from these cattle at least once per week after first administration.

Inoculation of the anti–PD-L1 chAb in BLV-infected cattle

To examine the antiviral efficacy of anti–PD-L1 chAb (BochG12; 21) in vivo, two cattle naturally infected with BLV (Table II) were inoculated i.v. with 1 mg/kg purified BochG12 (animal #5) or saline (as a control, animal #4). These animals were kept in a private dairy farm in Hokkaido. Peripheral blood samples were collected from both animals at least once per week after inoculation for measurement of proviral load as described.

Evaluation of combined COX-2 inhibition and PD-L1 blockade for reducing viral load in infected cattle

To investigate the in vivo antiviral effects of the combined treatment compared with monotherapy of anti–PD-L1 chAb, two BLV-infected cattle (animals #3 and #6) were inoculated with 1 mg/kg BochG12 (21), and animal #3 was also coadministered 0.5 mg/kg meloxicam (Metacam) by s.c. injection three times at weekly intervals (Table II). These animals were kept in an animal facility at the Faculty of Veterinary Medicine, Hokkaido University (Sapporo, Hokkaido, Japan). This animal experiment was approved by the Ethics Committee of the Faculty of Veterinary Medicine, Hokkaido University. Animal #3 was also used for the clinical study of meloxicam treatment alone and inoculated with BochG12 after a long interval (118 d) from the final administration of meloxicam. Peripheral blood samples were then collected from these cattle at least once per week after the inoculation of BochG12, and proviral loads were evaluated using qPCR as described.

Statistics

Differences were identified using the Dunnett test, Wilcoxon signed-rank test, and Steel–Dwass test. Correlation was analyzed using the Spearman correlation. A p value <0.05 was considered statistically significant. In clinical tests, we performed the quantification of proviral load by qPCR in triplicate. Using the value obtained from the experiments, we performed statistical analysis using a Dunnett test to test whether the proviral load at each point was significantly different from that at day 0.

Results

PGE₂ concentration changes with disease progression in BLV-infected cattle

Our previous report demonstrated an association between blood PGE₂ concentration and the progression of Johne disease, a chronic bacterial infection of cattle (22). Next, to investigate whether this immune dysfunction is specific to Johne disease or commonly occurred in bovine chronic infections, we focused on a chronic viral infection of cattle, BLV infection, which is known to show T cell dysfunction during the disease progression (14–16).

To examine whether PGE₂ is also associated with the progression of BLV infection, the plasma PGE₂ concentration was compared among uninfected, AL, and PL cattle by ELISA. The plasma concentration of PGE₂ was significantly higher in BLV-infected cattle compared with BLV-uninfected cattle (Fig. 1A). In addition, the plasma concentration of PGE₂ was positively correlated with the number of lymphocytes and BLV proviral load (Fig. 1B–D). Plasma PGE₂ concentration was also positively correlated with PD-L1 expression in IgM*B cells (Fig. 1E). Thus, PGE₂ production appears to increase with disease progression.

To identify the major cell type producing PGE₂ in the blood of BLV-infected cattle, the mRNA expression levels of COX2 were measured in total PBMCs, isolated CD21⁺ cells, and isolated CD14⁺ cells using qPCR (Table I). Consistent with plasma PGE₂ measurements, COX2 was significantly upregulated in PL cattle compared with AL and uninfected cattle (Fig. 1F–H). The production and release of PGE₂ were significantly higher in CD14⁺ cell cultures than CD21⁺ cell cultures from infected cattle (Fig. 1I), suggesting that CD14⁺ cells are the predominant source of PGE₂ in peripheral blood. Immunohistochemical analysis also revealed strong expression of PGE₂ and PD-L1 in B cell lymphoma tissues of EBL cattle but very weak expression in the healthy lymph nodes of BLV-uninfected cattle (Supplementary Fig. 1).

Finally, we measured the mRNA expression of EP4, EP2, and HPGD in PBMCs from BLV-infected and -uninfected cattle (Table I), and found that the expression of EP4 and EP2 was upregulated in PL cattle (Fig. 2A, 2B). By contrast, the mRNA expression of the PGE₂ catabolic enzyme gene HPGD was downregulated in PL cattle and was negatively associated with both BLV proviral load and serum PGE₂ concentration (Fig. 2C–E). Taken together, PGE₂ production and signaling are positively associated with disease progression in BLV-infected cattle. We then examined whether elevated PGE₂ actually drives disease progression by immune inhibition, particularly suppression of Th1 cell responses, thereby allowing for increased viral replication and gene expression.

Upregulation of PGE₂ production by BLV Ag

The capacity of BLV to evoke PGE₂ production was examined in PBMC cultures from BLV-infected and -uninfected cattle using the viral Ag FLK–BLV. FLK–BLV exposure for 6 d significantly upregulated PGE₂ production by PBMCs from infected AL and PL cattle (Fig. 3B, 3C) but not by PBMCs from uninfected cattle (Fig. 3A). This induced PGE₂ production was inhibited by the COX-2 inhibitor meloxicam (Fig. 3B, 3C). Collectively, these results showed that the COX-2/PGE₂ pathway was activated by the stimulation of BLV Ag in BLV-infected cattle.

Upregulation of gp51, G4, and R3 viral genes by PGE₂

A previous report demonstrated that PGE₂ can induce the expression of BLV viral genes such as tax (23). To examine PGE₂-induced viral expression in PBMCs, cells from BLV-infected cattle were cultured in the presence of PGE₂ for 3 d. Indeed, the
FIGURE 1. Kinetic analysis of PGE2 in cattle infected with BLV. (A) Plasma PGE2 concentration in cattle uninfected (n = 6) or infected with BLV (AL, n = 7; PL, n = 6) were determined using ELISA. (B–E) Positive correlation between the lymphocyte number (n = 13), proviral load (C: Japanese black cattle and first filial of Japanese black/Holstein cattle, n = 95; D: Holstein cattle, n = 30) or the percentages of PD-L1+ cells in IgM+ cells and plasma PGE2 concentration in cattle infected with BLV. (F–H) Quantification of COX2 mRNA expression in PBMCs [BLV (−), n = 7; AL, n = 7; PL, n = 7] and subpopulations of CD21+ [BLV (−), n = 4; AL, n = 7; PL, n = 6] and CD14+ [BLV (−), n = 4; AL, n = 5; PL, n = 6] cells derived from BLV-uninfected and BLV-infected cattle by qPCR. (I) Quantitation of PGE2 production in PBMCs, CD21+ cells, and CD14+ cells by ELISA (n = 8). Each symbol represents PGE2 concentration or relative expression level of each animal; pooled data from several experiments were analyzed by the Steel–Dwass test (A and F–I). Correlation statistic was analyzed using the Spearman correlation (B–E). BLV (−), BLV-uninfected cattle.
mRNA expression levels of *env* (*gp51*), *G4*, and *R3* were facilitated by PGE2 as measured by qPCR (Fig. 4A–C, Table I). To investigate the transduction mechanism, PBMCs of BLV-infected cattle were cultured with EP2 or EP4 agonist, both of which induced the expression of these three viral genes (Fig. 4D–F). Thus, the expression of BLV viral genes is regulated by PGE2 via its endogenous receptors EP2 and EP4.

### Activation of BLV-specific Th1 responses by the COX-2 inhibitor meloxicam in vitro

In humans, COX-2 inhibitors activate immune responses in vitro and in vivo (8, 9), and we previously reported that meloxicam activates Th1 responses of cattle in vitro (22). To examine whether meloxicam activates the BLV-specific Th1 responses, PBMCs from BLV-infected cattle were cultured in the presence of FLK–BLV plus meloxicam or vehicle, and T cell proliferation was measured by flow cytometry and Th1 cytokine production by ELISA (Fig. 5). The gating strategy and representative plots for CFSE staining are shown in Supplemental Fig. 2. The proliferation rates of both CD4+ and CD8+ cell populations were upregulated by meloxicam relative to vehicle (Fig. 5A, 5B), and the production levels of both IFN-γ and TNF-α were enhanced by meloxicam (Fig. 5C, 5D), consistent with the activation of BLV-specific Th1 responses.

### Activation of BLV-specific T cell responses in vitro by combined COX-2 inhibition and anti–PD-L1 Ab treatment

We then evaluated the immunomodulatory effects of combined COX-2 inhibition plus anti–PD-L1 Ab treatment on the BLV-specific Th1 cell response in vitro. The proliferation rates of CD4+ and CD8+ cells were significantly enhanced by combination treatment with meloxicam and anti–PD-L1 mAb (4G12) in the presence of FLK–BLV compared with the other treatment groups (Fig. 5E–G). The production of IFN-γ was also upregulated by combination treatment in the presence of FLK–BLV (Fig. 5G), and the stimulation of FLK, a negative control Ag, had no effect in either group (Fig. 5E–G). In addition, combined treatment with meloxicam and anti–PD-L1 chAb Boch4G12 significantly increased the proliferation of CD4+ and CD8+ cells and the production of IFN-γ compared with the other treatment groups (Fig. 5H–J). Collectively, these results demonstrate enhancement of BLV-specific Th1 responses by combined COX2 inhibitor and anti–PD-L1 Ab treatment in vitro.

### Antiviral effects of COX-2 inhibition in BLV-infected cattle

Three cattle naturally infected with BLV (animal #1–3) were administered 0.5 mg/kg meloxicam by s.c. injection once a week (Table II), and BLV proviral load was measured periodically from PBMCs. Consistent with antiviral efficacy, the proviral load fell significantly during the observation periods (Fig. 6A–C). To confirm whether Th1 cell responses were activated by the administration of meloxicam, the mRNA expression levels of IFN-γ were measured in PBMCs at several time points (days 0, 1, 7, 21, and 56) by qPCR (Table I). Expression was significantly higher on days 7, 21, and 56 compared with day 0 (Fig. 6D), indicating that COX-2 inhibitor administration induced sustained Th1-mediated antiviral effects in these BLV-infected cattle.

### In vivo antiviral effects of anti–PD-L1 chAb, Boch4G12 inoculation

Our previous report clearly demonstrated the antiviral effects of anti–PD-L1 chAb Boch4G12 in experimentally BLV-infected calf (21). In the current study, we examined the antiviral effects of anti–PD-L1 chAb Boch4G12 in naturally infected cattle (Table II). Animal #4 was inoculated with saline (as a negative control) and animal #5 was inoculated with 1 mg/kg Boch4G12, and peripheral blood samples were then collected periodically to measure the BLV proviral load in PBMCs. In animal #5, the proviral load decreased significantly after inoculation, and the viral load in animal #4 continued to rise (Fig. 6E, 6F). Therefore, Boch4G12 has antiviral effects on naturally infected BLV cattle in vivo.

### Antiviral efficacy of combined COX-2 inhibitor and anti–PD-L1 Ab treatment

Finally, we examined the antiviral efficacy of combined treatment compared with Boch4G12 treatment alone in two BLV-infected cattle (animals #3 and #6, Table II) with high proviral load (>2000 copies/50 ng DNA). Peripheral blood samples were collected from these cattle at least once per week for the measurement of BLV proviral...
load following treatment. Proviral load was not reduced in animal #6 by BochG12 treatment, but animal #3 exhibited significantly reduced viral load (nearly 80% at day 14) following combined treatment (Fig. 6G, 6H). Therefore, these findings demonstrate the potential of combined COX-2 inhibition plus anti–PD-L1 treatment as a new control strategy of BLV infection.

Discussion
In the advanced stages of BLV infection, BLV-specific Th1 responses are downregulated, leading to further disease progression and possible EBL (31). Several previous studies have demonstrated that loss of BLV-specific Th1 responses is mediated by upregulation of immunoinhibitory molecules such as PD-1 and PD-L1, as well as by expansion of regulatory T cells (15, 16, 24). Similarly, our previous study revealed that PGE2 suppresses Th1 responses, such as T cell proliferation and Th1 cytokine production, and induces the expression of PD-L1 (22). In addition, the expression levels of TGF-β1 and Foxp3, a key cytokine and transcription factor for the development of regulatory T cells, were increased in cultured bovine PBMCs by PGE2 treatment (Supplemental Fig. 3). In the current study, we found that the production of PGE2 increased in parallel with the progression of BLV infection. The expression of EP4 and EP2, PGE2 receptors associated with immune dysfunction (32), was also upregulated in the late stage of BLV infection, and the catabolic enzyme 15-PGDH was downregulated. Thus, PGE2 signaling may be markedly enhanced in late stage BLV infection, which, combined with the induction of PD-L1 and regulatory T cells via EP4 and EP2, would dramatically reduce BLV-specific Th1 responses.

Monocytes are a major source of PGE2 production (33). In this study, we identified the major cell type producing PGE2 in peripheral blood of BLV-infected cattle by the measurement of COX2 expression and PGE2 production in CD21+ cells and CD14+ cells. As shown in Fig. 1, COX2 expression was elevated in total PBMCs, CD21+ cells, and CD14+ cells of PL cattle compared with AL and uninfected cattle. The production capacity of PGE2 was higher in CD14+ cells than in CD21+ cells, suggesting that CD14+ cells are the main source of PGE2 production in the late stage of BLV infection.

In humans, transcription of COX-2 is induced by inflammatory cytokines, TLR signaling, and Ag stimulation via NF-κB (35, 36). In the current study, stimulation of PBMCs from BLV-infected cattle with BLV Ag induced PGE2 production. Generally, in the PBMC culture of the infected animals, BLV-specific CD4+ T cells mainly secrete Th1 cytokines, including TNF-α, by FLK–BLV stimulation. TNF-α is a key cytokine to induce the COX2 expression.
via NF-κB (36), suggesting that the BLV Ag upregulates COX2 expression via TNF-α–NF-κB pathway in BLV-infected cattle. In contrast, T cells from uninfected cattle could not respond to BLV Ag stimulation because of no acquired immunological memory against BLV. Our previous paper has demonstrated the same phenomenon in M. avium subsp. paratuberculosis–infected cattle. We observed the upregulation of PGE2 production and PD-L1 expression by the culture of PBMCs from M. avium subsp. paratuberculosis–infected cattle in the presence of M. avium subsp. paratuberculosis Ag, but not by that of PBMCs from uninfected cattle (22). Therefore, the acquired immunity might be necessary for the phenomena. Furthermore, in this study, the expression of HPGD was downregulated in PL cattle and negatively correlated with the BLV proviral load and serum PGE2 concentration. Taken together, coordinate regulation of increased PGE2 production and decreased PGE2 degradation leads to elevated levels of PGE2 which, in turn, suppresses BLV-targeted Th1 responses.

The viral gene gp51 encodes an envelope glycoprotein essential for cell-to-cell infection (37–40), and Tax, R3, and G4 are nonstructural
FIGURE 5. Activation of BLV-specific responses by the combination of meloxicam and anti–PD-L1 Ab. (A–D) PBMCs from BLV-infected cattle (A–C, n = 12; D, n = 8) were cultured with meloxicam in the presence of FLK–BLV. CD4+ (A) and CD8+ (B) cell proliferations were assayed by flow cytometry. IFN-γ (C) and TNF-α (D) productions were determined by ELISA. (E–G) PBMCs from BLV-infected cattle were incubated with meloxicam and anti–PD-L1 mAb in the presence of FLK or FLK–BLV. CD4+ (E: FLK, n = 7; FLK–BLV, n = 15) and CD8+ (F: FLK, n = 8; FLK–BLV, n = 24) cell proliferations were assayed by flow cytometry. IFN-γ production was determined by ELISA (G, FLK, n = 7; FLK–BLV, n = 20). (H–J) PBMCs from BLV-infected cattle were incubated with meloxicam and anti–PD-L1 chAb in the presence of FLK or FLK–BLV (H and I, n = 16; J, n = 18). CD4+ (H) and CD8+ (I) cell proliferations were assayed by flow cytometry. IFN-γ production was determined by ELISA (J). Symbols represent mean from single-culture wells of different individuals; pooled data from several experiments were analyzed by the Wilcoxon signed-rank test (A–D) and the Steel–Dwass test (E–J). Cont Ig, rat IgG (for E–G), or bovine IgG (for H–J); αPD-L1 chAb, anti–PD-L1 chAb (Boch4G12); αPD-L1 mAb: anti–PD-L1 mAb (4G12).
proteins involved in the activation of viral transcription and propagation (41–44). A previous report demonstrated that PGE2 promotes Tax expression in PBMCs isolated from BLV-infected cattle (23), and the current study showed that the expression levels of gsp51, G4, and R4 were also upregulated by PGE2 via EP2 and EP4 signaling in PBMCs isolated from BLV-infected cattle. Binding of PGE2 to EP2 and EP4 increases intracellular cAMP production (7), which activates protein kinase A (PKA) and downstream transcription factors that regulate genes with cAMP-response element (CRE) sites in the promoter. The BLV–long terminal repeat has a CRE that induces transcription of BLV gene (45, 46), strongly suggesting that PGE2/EP2 and PGE2/EP4 facilitate BLV viral gene transcription through activation of cAMP/PKA/CRE signaling.

CD8+ cytotoxic T cells activated by Th1 cytokines play a critical role in the control of BLV infection. COX-2 inhibitors are known to activate immune responses, including T cell responses (8, 9). Our previous report demonstrated that a selective COX-2 inhibitor, meloxicam, induced Th1 responses in PBMC cultures from both healthy cattle and cattle infected with M. avium subsp. paratuberculosis (22). In this study, meloxicam also activated BLV-specific Th1 responses in vitro, and administration of Metacam (a veterinary formulation of meloxicam) activated Th1 responses and significantly decreased proviral load in BLV-infected cattle. These findings suggest that inhibition of PGE2 using COX-2 inhibitors is a potential treatment strategy against BLV infection. Indeed, possible benefits of the COX-2 inhibitor celecoxib on the immune function were reported in patients with HIV infection (9). However, in the veterinary field, the current study is the first to investigate the therapeutic effects of COX-2 inhibitors against chronic infections.

In the current study, BLV proviral load was not dramatically reduced by treatment with meloxicam alone, probably because of the upregulation of immunoinhibitory molecules. Provisro load was extremely high (>2000 copies/50 ng DNA) in the cattle (animals #1–3) receiving meloxicam alone, and the expression of immunoinhibitory molecules, such as PD-L1, LAG-3, CTLA-4, Tim-3, and Foxp3, is substantially higher in BLV-infected cattle with high proviral loads compared with infected cattle with low proviral loads (16, 18, 19, 47, 48). Additionally, the proportions of CD4+ and CD8+ cells coexpressing PD-1 and LAG-3 increase in the late stage of BLV infection (49). Thus, the dual blockade of PGE2 and other immunoinhibitory molecules may be required to enhance the antiviral effects in advanced BLV infections.

In a murine model of chronic infection, PGE2 signaling via EP2 and EP4, impaired survival and the function of CD8+ CTLs, and CTL function was restored, and viral control was improved by combined blockade of the PGE2 and PD-1/PD-L1 signaling pathways (50). Furthermore, our previous study showed that PGE2 regulates PD-L1 expression in cattle and that the combined treatment with a COX-2 inhibitor plus an anti–PD-L1 Ab improves Th1 responses in Johne disease (22). Therefore, in this study, we evaluated the immunostimulative effects of combination treatment and found significantly enhanced BLV-specific Th1 responses in vitro.

Next, we performed the clinical study using BLV-infected cattle with high proviral load to evaluate antiviral effects of the treatment. We also examined the effects of monotherapy and combined therapy on high proviral load in BLV-infected cattle. Monotherapy with anti–PD-L1 chAb had no impact on BLV-infected cattle with high proviral load (animal #6), but combined treatment of animal #3 with the COX-2 inhibitor plus anti–PD-L1 chAb substantially reduced BLV proviral load to below 2000 copies/50 ng DNA from day 7 to day 49 after the first injection. Previous studies have demonstrated that BLV proviral load is positively correlated with vertical and horizontal transmission risks, and BLV-infected cattle with a high proviral load (>2000 copies/50 ng DNA) are the major source of transmission within a herd (26, 51, 52). Therefore, our findings suggest that the cotargeting of PGE2 and PD-L1 in the most severely infected animals could be a novel method for herd BLV infection control. In this study, although the number of the infected animals used in clinical tests was limited, much attention was paid to obtaining accurate data from these experiments. First, environmental influence was removed in the clinical tests of this study as much as possible. The clinical test of the single treatment of anti–PD-L1 chAb (animals #4 and #5) or the combined treatment (animals #3 and #6) was designed to compare the antiviral effect of the treatments between two BLV-infected animals and was conducted in the same facility at the same day and time, respectively. In contrast, three animals (animals #1–3) were launched for the clinical test of the COX-2 inhibitor and were kept at the three different locations in Hokkaido. These animals were administered the inhibitor at the same time of day on different days using the same injection method by a particular veterinarian. During all of the clinical tests, the tested animals were kept at “loose housing barn” and fed on equivalent grass, hay, and pellet. Additionally, all of the tested animals were not milked to prevent the influence of sex hormones and other biological changes during lactation. Second, all of the blood samples were kept at 4°C immediately after blood collection and shipped to the laboratory of Hokkaido University because the clinical tests were conducted at three totally different locations in Hokkaido. Then, PBMCs were isolated from the blood samples in the laboratory of Hokkaido University on the day after the blood collection to prevent nonspecific effects on results of the analysis caused by methods of shipping and storage. Finally, blood samples were collected at least once.

### Table II. Cattle used in clinical studies

<table>
<thead>
<tr>
<th>Cattle</th>
<th>#1</th>
<th>#2</th>
<th>#3 (Clinical Study of the COX-2 Inhibitor)</th>
<th>#4</th>
<th>#5</th>
<th>#6</th>
<th>#3 (Clinical Study of the Combined Treatment)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>43 mo old</td>
<td>96 mo old</td>
<td>47 mo old</td>
<td>19 mo old</td>
<td>13 mo old</td>
<td>76 mo old</td>
<td>52 mo old</td>
</tr>
<tr>
<td>Breed</td>
<td>Holstein</td>
<td>Holstein</td>
<td>Holstein</td>
<td>Holstein</td>
<td>Holstein</td>
<td>Holstein</td>
<td>Holstein</td>
</tr>
<tr>
<td>Sex</td>
<td>Female</td>
<td>Female</td>
<td>Female</td>
<td>Female</td>
<td>Female</td>
<td>Female</td>
<td>Female</td>
</tr>
<tr>
<td>Body weight</td>
<td>749 kg</td>
<td>736 kg</td>
<td>759 kg</td>
<td>433 kg</td>
<td>295 kg</td>
<td>799 kg</td>
<td>799 kg</td>
</tr>
<tr>
<td>Inoculation dose (Boch4G12)</td>
<td>0.5 mg/kg, once a week, total of nine times, s.c.</td>
<td>0.5 mg/kg, once a week, total of nine times, s.c.</td>
<td>0.5 mg/kg, once a week, total of five times, s.c.</td>
<td>0.5 mg/kg, once a week, total of three times, s.c.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
FIGURE 6. Clinical tests using BLV-infected cattle. (A–C) BLV-infected cattle were administered 0.5 mg/kg of meloxicam, s.c. (D) The expression of IFN-γ at days 0, 1, 7, 28, and 56 was quantitated by qPCR in triplicate. (E and F) BLV-infected cattle were inoculated with 1 mg/kg of the purified anti–PD-L1 chAb (Boch4G12, animal #5) or saline (control, animal #4), i.v. (G and H) BLV-infected cattle (animals #3 and #6) were inoculated with 1 mg/kg of the purified Boch4G12, i.v. In addition, animal #3 was administered 0.5 mg/kg meloxicam once a week (total of three times) s.c. Proviral loads of these cattle were measured by qPCR in triplicate, and data are presented mean ± SD (A–C and E–H). Statistical significance was determined by the Dunnett test (A–H). *p < 0.05 versus day 0.
The Journal of Immunology 1323

per week, and qPCR was performed for the detection of BLV proviral load in triplicate to reduce experimental error. The result of these clinical tests requires confirmation in further clinical trials with larger numbers of the infected cattle from different herds or farms. To the best of our knowledge, no previous human or veterinary study has investigated the benefits of combining a COX-2 inhibitor with an Ab targeting immune checkpoint molecules in vivo. Thus, our findings may provide a novel strategy for control of chronic retrovirus infection in both humans and livestock.

Recently, several studies have demonstrated an association between PGE2 elevation and upregulated expression of other immunoinhibitory molecules, such as PD-1, in human cancer (53, 54). In addition, dual blockade of PGE2 and PD-1 improved tumor eradication in a mouse model (55). However, the associations between PGE2 and other immunoinhibitory molecules are generally unclear. Further study is warranted to investigate these associations using bovine chronic infection as a disease model.

Although BLV infection is endemic in many countries (12, 56–59), there are no effective therapies or vaccines. Therefore, a novel strategy is required for effective BLV infection control. Our current work is a pilot study to assess the potential efficacies of pharmacological COX-2 inhibition and combined COX-2 and PD-1/PD-L1 inhibition. Treatment with the COX-2 inhibitor meloxicam with or without anti-PD-L1 Ab demonstrated an antiviral activity in BLV-infected cattle. Additional experiments using larger numbers of infected cattle are required to confirm the efficacy of these novel treatments. Finally, better understanding of the molecular mechanisms underlying immune dysfunction by PGE2 and the associations with other immune dysfunctional pathways is essential for the development of improved antiviral and anti-bacterial treatments.

Acknowledgments
We are grateful to Dr. Hideyuki Takahashi, Dr. Yasuyuki Mori, and Dr. Tomio Ibayashi for valuable advice and discussions. We thank Enago for the English language review.

Disclosures
K.Y. and M.T. are employed by Fuso Pharmaceutical Industries, Ltd. Y. Sajiki, S.K., T.O., A.N., N.M., S.G., Y. Suzuki, S.M., and K.O. are authors of a patent application covering materials and techniques described in this paper (PCT/JP2018/27041). The other authors have no financial conflicts of interest.

References

Downloaded from http://www.jimmunol.org at Nankodo Co Ltd Tohoku Univ/Immunol Info Sec/Ink.Inst.jp on September 13, 2019


